The investigators hypothesize that abnormalities in thromboelastography (TEG) parameters in patients with liver, pancreas, biliary, esophageal, colorectal, and lung adenocarcinoma can serve as biomarkers for oncologic disease burden, cancer recurrence and overall survival as well as thrombotic and hemorrhagic post-operative complications. The investigators further hypothesize that there is histologic pathology correlates to pre-operative TEG abnormalities, and that it identifies patients with virulent tumor biology.
new diagnosis by the providing physician of hepatopancreaticobiliary, esophageal, colorectal, lung adenocarcinoma, or liver metastasis of any origin will be eligible for enrollment in the study
18 Years and older
Under 18 years old
prisoners
unable to provide informed consent
pregnant women
Patients who are evaluated at the University of Colorado Cancer Center with a new diagnosis by the providing physician of hepatopancreaticobiliary, esophageal, colorectal or lung adenocarcinoma will be eligible for enrollment in the study.
Case-control
Prospective
TEG indices
Diagnostic testBlood samples
TEG indices of coagulation
R time (minutes \~ coagulation factors), angle (degrees \~ fibrinogen function), MA (mm \~ platelets function), and LY30 (%\~ fibrinolysis) measured at baseline (initial presentation or time of diagnosis), after neoadjuvant chemotherapy (if applicable), pre-operatively (before the induction of general anesthesia), intra-operatively (after tumor removal), post-operative days 1, 3 and 5, and at routine follow up appointments at 2 weeks, 3 months, 6 months and 1 year after surgery.
Disease burden as measured by TNM staging
Disease burden as measured by TNM staging
Pre- operative thrombotic and hemorrhagic complications.
Pre-operative thrombotic and hemorrhagic complications.
Recurrence free and overall survival.
Recurrence free and overall survival.
Tumor Type
Benign, pre-malignant, malignant
Number of patients with pre-operative nodal
Benign, pre-malignant, malignant
Number of patients withneuronal invasion
neuronal invasion
Number of patients with mass resectability
mass resectability
Click on the lead sponsor to view all of their trials.
University of Colorado, Denver
Lead sponsor
Haemonetics Corporation
Collaborator
